TY - JOUR
T1 - Adrenergic-pathway gene variants influence beta-blockerrelated outcomes after acute coronary syndrome in a race-specific manner
AU - Cresci, Sharon
AU - Dorn, Gerald W.
AU - Jones, Philip G.
AU - Beitelshees, Amber L.
AU - Li, Allie Y.
AU - Lenzini, Petra A.
AU - Province, Michael A.
AU - Spertus, John A.
AU - Lanfear, David E.
N1 - Funding Information:
This work and Dr. Cresci's effort are supported in part by the National Institutes of Health (Cresci NR013396 and NIH Specialized Center for Clinically-Oriented Research [SCCOR] in Cardiac Dysfunction and Disease P50 HL077113 ) and the Longer Life Foundation. Dr. Lanfear's effort is supported in part by the National Institutes of Health (Lanfear HL085124 , HL103871 ). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PY - 2012/9/4
Y1 - 2012/9/4
N2 - Overcoming racial differences in acute coronary syndrome (ACS) outcomes is a strategic goal for U.S. health care. Genetic polymorphisms in the adrenergic pathway seem to explain some outcome differences by race in other cardiovascular diseases treated with β-adrenergic receptor blockade (BB). Whether these genetic variants are associated with survival among ACS patients treated with BB, and if this differs by race, is unknown. β-adrenergic receptor blockade after ACS is a measure of quality care, but the effectiveness across racial groups is less clear. A prospective cohort of 2,673 ACS patients (2,072 Caucasian; 601 African-American) discharged on BB from 22 U.S. hospitals were followed for 2 years. Subjects were genotyped for polymorphisms in ADRB1, ADRB2, ADRA2C, and GRK5. We used proportional hazards regression to model the effect of genotype on mortality, stratified by race and adjusted for baseline factors. The overall 2-year mortality rate was 7.5% for Caucasians and 16.7% for African Americans. The prognosis associated with different genotypes in these BB-treated patients differed by race. In Caucasians, ADRA2C 322-325 deletion carriers had significantly lower mortality as compared with homozygous individuals lacking the deletion (hazard ratio: 0.46; confidence interval [CI]: 0.21 to 0.99; p = 0.047; race × genotype interaction p = 0.053). In African Americans, the ADRB2 16R allele was associated with significantly increased mortality (hazard ratio for RG vs. GG: 2.10; CI: 1.14 to 3.86; RR vs. GG: 2.65; CI: 1.38 to 5.08; p = 0.013; race × genotype interaction p = 0.096). Adrenergic pathway polymorphisms are associated with mortality in ACS patients receiving BB in a race-specific manner. Understanding the mechanism by which different genes impact post-ACS mortality differently in Caucasians and African Americans might illuminate opportunities to improve BB therapy in these groups.
AB - Overcoming racial differences in acute coronary syndrome (ACS) outcomes is a strategic goal for U.S. health care. Genetic polymorphisms in the adrenergic pathway seem to explain some outcome differences by race in other cardiovascular diseases treated with β-adrenergic receptor blockade (BB). Whether these genetic variants are associated with survival among ACS patients treated with BB, and if this differs by race, is unknown. β-adrenergic receptor blockade after ACS is a measure of quality care, but the effectiveness across racial groups is less clear. A prospective cohort of 2,673 ACS patients (2,072 Caucasian; 601 African-American) discharged on BB from 22 U.S. hospitals were followed for 2 years. Subjects were genotyped for polymorphisms in ADRB1, ADRB2, ADRA2C, and GRK5. We used proportional hazards regression to model the effect of genotype on mortality, stratified by race and adjusted for baseline factors. The overall 2-year mortality rate was 7.5% for Caucasians and 16.7% for African Americans. The prognosis associated with different genotypes in these BB-treated patients differed by race. In Caucasians, ADRA2C 322-325 deletion carriers had significantly lower mortality as compared with homozygous individuals lacking the deletion (hazard ratio: 0.46; confidence interval [CI]: 0.21 to 0.99; p = 0.047; race × genotype interaction p = 0.053). In African Americans, the ADRB2 16R allele was associated with significantly increased mortality (hazard ratio for RG vs. GG: 2.10; CI: 1.14 to 3.86; RR vs. GG: 2.65; CI: 1.38 to 5.08; p = 0.013; race × genotype interaction p = 0.096). Adrenergic pathway polymorphisms are associated with mortality in ACS patients receiving BB in a race-specific manner. Understanding the mechanism by which different genes impact post-ACS mortality differently in Caucasians and African Americans might illuminate opportunities to improve BB therapy in these groups.
KW - pharmacogenetics
KW - racial disparities.
KW - β-blocker therapy
UR - http://www.scopus.com/inward/record.url?scp=84865502728&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2012.02.051
DO - 10.1016/j.jacc.2012.02.051
M3 - Article
C2 - 22703928
AN - SCOPUS:84865502728
SN - 0735-1097
VL - 60
SP - 898
EP - 907
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 10
ER -